Ni‐Chun Tsai

1.4k total citations
48 papers, 712 citations indexed

About

Ni‐Chun Tsai is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Ni‐Chun Tsai has authored 48 papers receiving a total of 712 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 26 papers in Pathology and Forensic Medicine and 20 papers in Hematology. Recurrent topics in Ni‐Chun Tsai's work include Lymphoma Diagnosis and Treatment (26 papers), Hematopoietic Stem Cell Transplantation (11 papers) and Acute Lymphoblastic Leukemia research (10 papers). Ni‐Chun Tsai is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), Hematopoietic Stem Cell Transplantation (11 papers) and Acute Lymphoblastic Leukemia research (10 papers). Ni‐Chun Tsai collaborates with scholars based in United States, Netherlands and Israel. Ni‐Chun Tsai's co-authors include Joycelynne Palmer, Stephen J. Forman, Auayporn Nademanee, Sandra H. Thomas, Robert Chen, Len Farol, Amrita Krishnan, Leslie Popplewell, David Smith and Joshua D.I. Ellenhorn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Ni‐Chun Tsai

44 papers receiving 701 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ni‐Chun Tsai United States	16	382	321	242	130	103	48	712
Deepa Jagadeesh United States	17	652 1.7×	660 2.1×	169 0.7×	170 1.3×	273 2.7×	123	1.1k
Michela Cerno Italy	14	234 0.6×	149 0.5×	372 1.5×	158 1.2×	77 0.7×	32	653
Pierre Brousset France	10	296 0.8×	314 1.0×	130 0.5×	91 0.7×	85 0.8×	23	582
J. L. Harousseau France	14	293 0.8×	187 0.6×	436 1.8×	133 1.0×	163 1.6×	35	812
Amin Alousi United States	12	356 0.9×	294 0.9×	558 2.3×	272 2.1×	218 2.1×	16	886
Sumithira Vasu United States	13	380 1.0×	93 0.3×	424 1.8×	231 1.8×	120 1.2×	78	851
Nobuhiko Uoshima Japan	15	311 0.8×	178 0.6×	336 1.4×	170 1.3×	153 1.5×	58	839
Taner Demirer Türkiye	11	493 1.3×	118 0.4×	689 2.8×	132 1.0×	132 1.3×	22	976
Ronit Gurion Israel	17	381 1.0×	344 1.1×	237 1.0×	102 0.8×	216 2.1×	83	830
A.-M. Stoppa France	14	484 1.3×	240 0.7×	537 2.2×	133 1.0×	130 1.3×	22	970

Countries citing papers authored by Ni‐Chun Tsai

Since Specialization

Citations

This map shows the geographic impact of Ni‐Chun Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ni‐Chun Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ni‐Chun Tsai more than expected).

Fields of papers citing papers by Ni‐Chun Tsai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ni‐Chun Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ni‐Chun Tsai. The network helps show where Ni‐Chun Tsai may publish in the future.

Co-authorship network of co-authors of Ni‐Chun Tsai

This figure shows the co-authorship network connecting the top 25 collaborators of Ni‐Chun Tsai. A scholar is included among the top collaborators of Ni‐Chun Tsai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ni‐Chun Tsai. Ni‐Chun Tsai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mei, Matthew, Joycelynne Palmer, Hun Ju Lee, et al.. (2025). Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma. HemaSphere. 9(5). e70126–e70126.

Pullarkat, Vinod, Lisa S. Chen, Joycelynne Palmer, et al.. (2023). A phase 1 trial of 8‐chloro‐adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics. Cancer. 130(5). 727–739. 2 indexed citations

Kasparian, Saro, Ni‐Chun Tsai, Joycelynne Palmer, et al.. (2023). A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy. The Oncologist. 28(8). 699–705. 7 indexed citations

Malki, Monzr M. Al, Joycelynne Palmer, Ni‐Chun Tsai, et al.. (2022). Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood Advances. 6(14). 4098–4106. 15 indexed citations

Malki, Monzr M. Al, Ni‐Chun Tsai, Joycelynne Palmer, et al.. (2021). Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. Blood Advances. 5(12). 2650–2659. 32 indexed citations

Ali, Haris, Ni‐Chun Tsai, Timothy W. Synold, et al.. (2021). Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Advances. 6(5). 1444–1453. 24 indexed citations

Zain, Jasmine M., Jennifer Simpson, Joycelynne Palmer, et al.. (2020). Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen". Blood. 136(Supplement 1). 10–11. 1 indexed citations

Mei, Matthew, Ni‐Chun Tsai, Sally Mokhtari, et al.. (2020). Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 26(8). 1425–1432. 3 indexed citations

Salhotra, Amandeep, Liana Nikolaenko, Lu Chen, et al.. (2019). Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center. Blood. 134(Supplement_1). 5729–5729. 1 indexed citations

10.

Chen, Robert W., Joycelynne Palmer, Sarah Tomassetti, et al.. (2018). Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. Journal of Hematology & Oncology. 11(1). 87–87. 17 indexed citations

11.

Rosenzweig, Michael, Joycelynne Palmer, Ni‐Chun Tsai, et al.. (2017). Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial. Blood. 130. 3144–3144.

12.

Aldoss, Ibrahim, Ni‐Chun Tsai, Marilyn L. Slovak, et al.. (2016). Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 22(7). 1212–1217. 8 indexed citations

13.

Khaled, Samer K., Joycelynne Palmer, Josef Herzog, et al.. (2015). Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 22(2). 268–276. 34 indexed citations

14.

Mei, Matthew, Mariëlle J. Wondergem, Joycelynne Palmer, et al.. (2014). Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen. Biology of Blood and Marrow Transplantation. 20(12). 2072–2075. 11 indexed citations

15.

Khaled, Samer K., Joycelynne Palmer, Josef Herzog, et al.. (2014). Drug Metabolism Gene Polymorphisms Influence Tacrolimus/Sirolimus Blood Levels and Incidence of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 124(21). 2492–2492.

16.

Chen, Robert, Joycelynne Palmer, Ni‐Chun Tsai, et al.. (2014). Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 20(11). 1864–1868. 45 indexed citations

17.

Krishnan, Amrita, Joycelynne Palmer, Ni‐Chun Tsai, et al.. (2011). Matched-Cohort Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy versus Total Body Irradiation–Based Conditioning for Poor-Risk Diffuse Large Cell Lymphoma. Biology of Blood and Marrow Transplantation. 18(3). 441–450. 29 indexed citations

18.

Nademanee, Auayporn, Joycelynne Palmer, Leslie Popplewell, et al.. (2011). High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma (PTCL): Analysis of Prognostic Factors. Biology of Blood and Marrow Transplantation. 17(10). 1481–1489. 27 indexed citations

19.

Krishnan, Amrita, Joycelynne Palmer, John A. Zaia, et al.. (2010). HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for Non-Hodgkin Lymphoma (NHL). Biology of Blood and Marrow Transplantation. 16(9). 1302–1308. 40 indexed citations

20.

Podnos, Yale D., Ni‐Chun Tsai, David Smith, & Joshua D.I. Ellenhorn. (2006). Factors Affecting Survival in Patients with Anal Melanoma. The American Surgeon. 72(10). 917–920. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact